Area of research
Pulmonary and Respiratory Medicine · Emergency Medical Services
Research interest
Research interests include Cystic Fibrosis Research Advances, Neonatal Respiratory Health Research, Tracheal and airway disorders, and Pediatric health and respiratory diseases.
Variability: the law of life?
PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report
PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report.
Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges.
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for <i>F508del</i> and a minimal function mutation: results from a 96-week open-label extension study.
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension Study.
Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials
Utility and interpretation of multiple breath washout in children with cystic fibrosis.
Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.
Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age.
Managing an ageing cystic fibrosis population: challenges and priorities.
Readability and complexity of written information presented to hospitalised patients for trial consent during the COVID-19 pandemic in the UK: a retrospective document analysis.
Qualitative Experiences and Depression/Anxiety Scores in Parents of Children With Cystic Fibrosis Transmembrane Conductance Regulator Related Metabolic Syndrome.
Spirometry thresholds for clinical trial eligibility: time for urgent re-evaluation.
A standard operating procedure for reducing risk from medications prohibited during clinical trials in cystic fibrosis.
Potential gene therapies for cystic fibrosis: a plain language summary for non-specialists and the lay community
Qualitative experiences and depression/ anxiety scores in parents of children with Cystic Fibrosis Transmembrane Related Metabolic Syndrome
Standards for the care of people with cystic fibrosis; establishing and maintaining health.
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
Standards for the care of people with cystic fibrosis (CF); Planning for a longer life.
Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target
Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial.
Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target.
Chronic rhinosinusitis in the era of CFTR modulator therapy.
Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis.